Clinical Trial Update: Tauroursodeoxycholic Acid (TUDCA) Plus Camrelizumab and Regorafenib in Hepatocellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and Bevacizumab [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating Tauroursodeoxycholic acid (TUDCA) in combination with camrelizumab and regorafenib for hepatocellular carcinoma in patien…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Camrelizumab (camrelizumab)
• Regorafenib (regorafenib)
• TUDCA (Tauroursodeoxycholic acid)

Snippet

Sponsor: Fudan University | Conditions: Hepatocellular Carcinoma (HCC) | Phase 2 | Status: RECRUITING